2023 was a robust 12 months for drug discovery. Mullard et al. (2024) report:
The FDA’s Heart for Drug Analysis and Analysis (CDER) accredited 55 new medicine in 2023, because the small molecule and biologic pharmacopoeia continues to develop. This cohort is sort of 50% greater than the brand new approval class of 2022, which fell under the approval pattern line. The ten-year rolling common for brand new CDER approvals now stands at 46 per 12 months, the best it has been in over 20 years. The nadir was 2010, when this common bottomed out at 25 per 12 months.
The total listing of approvals might be discovered right here.
